The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma

Bujko,Mateusz; Kowalewska,Magdalena; Danska-Bidzinska,Anna; Bakula-Zalewska,Elwira; Siedecki,Janusz  A.; Bidzinski,Mariusz

doi:10.3892/ol.2012.771

The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma

Authors:
- Mateusz Bujko
- Magdalena Kowalewska
- Anna Danska-Bidzinska
- Elwira Bakula-Zalewska
- Janusz A. Siedecki
- Mariusz Bidzinski
View Affiliations

Affiliations: Department of Molecular Biology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 02-781 Warsaw, Poland, Department of Gynecological Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 02-781 Warsaw, Poland, Department of Pathology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 02-781 Warsaw, Poland
Published online on: June 22, 2012 https://doi.org/10.3892/ol.2012.771
Pages: 551-555

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) gene promoter hypermethylation is observed in a number of solid tumors and is correlated with the silencing of MGMT expression. In glioblastoma patients treated with the alkylating agent temozolomide, MGMT gene methylation status was shown to have predictive value in terms of prolonged overall survival. Recently, temozolomide has demonstrated promising activity in the treatment of soft tissue sarcomas, including those of the uterus. The tissue specimens involving tumor samples and normal uterine fragments were obtained from nine patients with smooth muscle uterine sarcoma, 11 with stromal uterine sarcoma and 17 with mixed uterine tumors. MGMT gene promoter methylation was analyzed by combined bisulfite restriction analysis (COBRA) while its expression levels were assessed using the real-time reverse transcription polymerase chain reaction (qRT-PCR). MGMT promoter methylation was observed in 27% of all tumor samples analyzed. When stratified by the disease type, 55.5% (5/9) of smooth muscle sarcomas, 23.5% (4/17) of mixed uterine tumor tissues and 9% (1/11) of stromal sarcomas showed MGMT methylation. The MGMT promoter methylation was associated with lower levels of gene expression in tumors when compared with those with an unmethylated promoter (P=0.0232) or normal tissues (P=0.0141). To conclude, MGMT promoter methylation and downregulation of gene expression is observed in a fraction of carcinosarcomas and non-epithelial malignant tumors of corpus uteri. The assessment of MGMT promoter methylation status may potentially identify patients who would benefit from temozolomide treatment.

View Figures

View References

1	Brooks SE, Zhan M, Cote T and Baquet CR: Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 93:204–208. 2004.PubMed/NCBI
2	D’Angelo E and Prat J: Uterine sarcomas: a review. Gynecol Oncol. 116:131–139. 2010.
3	Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 71(Suppl 4): 1702–1709. 1993. View Article : Google Scholar : PubMed/NCBI
4	Zagouri F, Dimopoulos AM, Fotiou S, Kouloulias V and Papadimitriou CA: Treatment of early uterine sarcomas: disentangling adjuvant modalities. World J Surg Oncol. 7:382009. View Article : Google Scholar : PubMed/NCBI
5	Ryan CW, Dolan ME, Brockstein BB, et al: A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 58:634–639. 2006. View Article : Google Scholar : PubMed/NCBI
6	Woll PJ, Judson I, Lee SM, et al: Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 35:410–412. 1999. View Article : Google Scholar : PubMed/NCBI
7	Trent JC, Beach J, Burgess MA, et al: A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 98:2693–2699. 2003. View Article : Google Scholar : PubMed/NCBI
8	Talbot SM, Keohan ML, Hesdorffer M, et al: A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 98:1942–1946. 2003. View Article : Google Scholar : PubMed/NCBI
9	Garcia del Muro X, Lopez-Pousa A, Martin J, et al; Spanish Group for Research on Sarcomas. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 104:1706–1712. 2005.
10	Anderson S and Aghajanian C: Temozolomide in uterine leiomyosarcomas. Gynecol Oncol. 98:99–103. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ferriss JS, Atkins KA, Lachance JA, Modesitt SC and Jazaeri AA: Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer. 20:120–125. 2010. View Article : Google Scholar : PubMed/NCBI
12	Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793–797. 1999.PubMed/NCBI
13	Herfarth KK, Brent TP, Danam RP, et al: A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 24:90–98. 1999. View Article : Google Scholar : PubMed/NCBI
14	Kaina B, Fritz G, Mitra S and Coquerelle T: Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis. 12:1857–1867. 1991. View Article : Google Scholar : PubMed/NCBI
15	Franceschi E, Tosoni A, Pozzati E and Brandes AA: Association between response to primary treatments and MGMT status in glioblastoma. Expert Rev Anticancer Ther. 8:1781–1786. 2008. View Article : Google Scholar : PubMed/NCBI
16	Hassel JC, Sucker A, Edler L, et al: MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer. 103:820–826. 2010. View Article : Google Scholar : PubMed/NCBI
17	Smith E, Jones ME and Drew PA: Quantitation of DNA methylation by melt curve analysis. BMC Cancer. 9:1232009. View Article : Google Scholar : PubMed/NCBI
18	Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E and Bidzinski M: Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors. Clin Biochem. 45:368–371. 2012. View Article : Google Scholar : PubMed/NCBI
19	Cui W, Taub DD and Gardner K: qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res. 35:D805–809. 2007. View Article : Google Scholar : PubMed/NCBI
20	Jacinto FV and Esteller M: MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst). 6:1155–1160. 2007. View Article : Google Scholar : PubMed/NCBI
21	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
22	Preusser M, Charles Janzer R, Felsberg J, et al: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18:520–532. 2008.